Acorda Therapeutics is a drug manufacturers - specialty & generic business based in the US. Acorda Therapeutics shares (ACOR) are listed on the NASDAQ and all prices are listed in US Dollars. Acorda Therapeutics employs 102 staff and has a trailing 12-month revenue of around $117.6 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.61 - $18.00 |
|---|---|
| 50-day moving average | $9.33 |
| 200-day moving average | $12.55 |
| Wall St. target price | $10.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-203.57 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Acorda Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Acorda Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Acorda Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.51. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Acorda Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Acorda Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $8.4 million.
The EBITDA is a measure of a Acorda Therapeutics's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $117.6 million |
|---|---|
| Operating margin TTM | 3.9% |
| Gross profit TTM | $82.4 million |
| Return on assets TTM | -5.77% |
| Return on equity TTM | -23.68% |
| Profit margin | -214.95% |
| Book value | $-127.17 |
| Market Capitalization | $821,028 |
TTM: trailing 12 months
We're not expecting Acorda Therapeutics to pay a dividend over the next 12 months.
Acorda Therapeutics's shares were split on a 1:20 basis on 4 June 2023 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Acorda Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Acorda Therapeutics shares which in turn could have impacted Acorda Therapeutics's share price.
Over the last 12 months, Acorda Therapeutics's shares have ranged in value from as little as $0.6116 up to $18. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acorda Therapeutics's is 1.462. This would suggest that Acorda Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Acorda Therapeutics, Inc. , a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.